NCT02395250已完成1 期
Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Adverse events attributed to the administration of the anti-GPC3 CAR T cells
研究概览
简要总结
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age of 18-70 years;
- •Pathologically confirmed advanced hepatocellular carcinoma (HCC);
- •≥1 measurable target lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1);
- •Tumor tissue positive for GPC3 expression per immunohistochemical staining (IHC) assay;
- •Estimated survival > 12 weeks;
- •Child-Pugh grade A;
- •ECOG performance score of 0-1;
- •HBV-DNA < 200 IU/mL if positive for HBsAg or HBcAb. Patients positive for HBsAg shall receive anti-viral treatment per "The guideline of prevention and treatment for chronic hepatitis B: a 2015 update";
- •Have adequate venous access for apheresis or venous blood collection;
- •White blood cells ≥ 2.5 x 109/L, platelet ≥ 60×109/L, haemoglobin ≥ 9.0 g/dL, lymphocyte ≥ 0.4×109/L
- •Serum albumin ≥ 30 g/dL, serum lipase and amylase≤1.5 upper limit of normal (ULN), serum creatinine ≤ 1.5 ULN and endogenous creatinine clearance ≥ 40mL/min, ALT and AST ≤ 5 ULN, Serum total bilirubin ≤ 2.5 ULN, Prothrombin Time is less than 4s longer than normal;
- •Negative serum pregnancy test within 14 days before CAR T infusion, and with willingness to use reliable contraceptive methods to avoid pregnancy until 12 months after CAR T infusions for females of childbearing age; Having undergone sterilization procedure or with willingness to use reliable contraceptive methods to avoid pregnancy for males with female partner of childbearing age during the study;
- •Able to understand and sign the informed consent form
排除标准
- •If the patient meets any of the exclusion criteria, the patient must be excluded from the study.
- •Pregnant or lactating female patients;
- •Positive serum tests for HCV, HIV, or syphilis;
- •Presence of HBV/HCV coinfection;
- •Presence of any uncontrollable active infection, such as, but not limited to, active tuberculosis
- •History of systemic administration of steroids (not including inhaled steroids), or other immunosuppressant drugs within 2 weeks before apheresis;
- •History of allergy to immunotherapy and related drugs, or β-lactam antibiotics, or history of other severe allergy;
- •History or current presence of hepatic encephalopathy;
- •Presence of ascites with clinical significance that is defined as positive focused physical examination for ascites, or ascites that requires treatment intervention (not including any ascites shown on image examinations without the need for clinical intervention);
- •≥ 50% of normal liver occupied with HCC tumor tissue, or presence of tumor thrombus in the portal vein, or mesenteric vein, or inferior vena based on image analysis;
- •Presence of HCC metastatic lesion in the central nervous system, or presence of other diseases of central nervous system with clinical significance;
- •Presence of heart disease that requires treatment intervention, or poorly controlled hypertension (systolic pressure > 160 mmHg, or diastolic pressure > 100 mmHg);
- •Presence of active auto-immune disease that requires immunosuppressant treatment;
- •History of organ transplantation or currently on the waiting list for organ transplantation, including, but not limited to, liver transplantation;
- •Anti-HCC therapies including, but not limited to, surgical resection, interventional therapy, radiation therapy, chemotherapy, and immunotherapy, within 2 weeks before apheresis;
- •History of receiving anti-PD-1 or anti-PD-L1 monoclonal antibodies, or other immunotherapy;
- •History of other malignancies in the past 5 years, or presence of other active malignancies (not including cervical cancer in situ and basal cell carcinomas);
- •Presence of other serious diseases or conditions, including uncontrolled diabetes (HbA1c > 7% with treatment); severe cardiac dysfunction with LVEF < 45%; myocardial infarction, unstable angina, or unstable arrhythmia in the past 6 months pulmonary embolism; chronic obstructive pulmonary disease; interstitial lung disease; forced expiratory volume in 1 second (FEV1) < 60%, gastric ulcer; history of gastrointestinal bleeding, or confirmed tendency for gastrointestinal bleeding;
- •Determined by the investigator to be lack of compliance for the study.
研究组 & 干预措施
anti-GPC3 CAR T
Experimental
干预措施: anti-GPC3 CAR T (Biological)
结局指标
主要结局
Adverse events attributed to the administration of the anti-GPC3 CAR T cells
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFRAdvanced GliomaNCT02331693RenJi Hospital10
已完成
不适用
CAR-GPC3 T Cells in Patients With Refractory Hepatocellular CarcinomaHepatocellular CarcinomaNCT03146234RenJi Hospital7
Unknown
1 期
CD19-redirected Autologous Cells (CAR-CD19 T Cells)CD19 Positive Malignant B-cell Leukemia and LymphomaNCT02933775RenJi Hospital45
招募中
1 期
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT06461624Zhejiang University15
招募中
1 期
IMC001 for Clinical Research on Advanced Digestive System MalignanciesAdvanced Hepatocellular CarcinomaAdvanced Colorectal CancerAdvanced Gastric CancerAdvanced Pancreatic CancerNCT05028933Zhejiang University48